Kaveh Abri Aghdamkaveh.abri@gmail.comEye Research Center, The Five Senses Health Institute, Department of Ophthalmology, School of Medicine, Iran University of Medical Sciences, Tehran

Samira Chaibakhshsmr.chaibakhsh@gmail.comRajaie Cardiovascular Medical and Research Institute, Iran University of Medical Sciences, Tehran,

Nazanin Hasaninazanin.has9@gmail.comEye Research Center, The Five Senses Health Institute, Department of Ophthalmology, School of Medicine, Iran University of Medical Sciences, Tehran,

Vahid Zare Hosseinabadizareha.vahid@gmail.comEye Research Center, The Five Senses Health Institute, Department of Ophthalmology, School of Medicine, Iran University of Medical Sciences, Tehran,

Ali Aghajanialiaghajani_y@yahoo.comIsfahan Eye Research Center, Department of Ophthalmology, Isfahan University of Medical Sciences, Isfahan,

Purpose: This study aims to assess the biometric alterations contributing to myopia in children who have undergone treatment for retinopathy of prematurity (ROP) and compare these changes with those observed in full-term myopic children.
Methods: Children who had undergone ROP treatment were recruited and classified according to their treatment methods. An age-matched group of myopic patients with no history of ROP treatment was also included. Complete perinatal history was collected, and a comprehensive ophthalmic examination, including cycloplegic refraction, was conducted. The biometric data of children in each study group were gathered using the IOL Master and Pentacam.
Results: The study recruited 14 patients in the intravitreal bevacizumab (IVB) group, 17 patients in the laser-treated group, and 13 individuals in the control group. There was no significant difference between the two patient groups regarding gestational age, birth weight, and age. In the IVB group, 50% of patients were myopic, compared to 52.9% in the laser-treated group. The incidence of high myopia was significantly higher in the laser-treated group (P < 0.001). In the non-myopic group, changes in refractive error were solely related to changes in axial length (P = 0.003). However, in the myopic group, changes in refractive error were significantly associated with changes in anterior chamber depth (P < 0.001), lens thickness (P < 0.001), and axial length (P = 0.018). Furthermore, myopic children in the ROP group had significantly shorter axial lengths, shallower anterior chambers, thicker lenses, and steeper corneas compared to the control group (all P < 0.001).
Conclusion: Eyes with a history of ROP treatment, whether myopic or non-myopic, should be considered distinct entities. In patients who have undergone ROP treatment and have not developed myopia, changes in refractive error are primarily influenced by alterations in axial length, rather than changes in the anterior segment. Furthermore, children with myopia and a history of treatment for ROP (either IVB or laser) exhibit different biometric changes compared to myopic children without a history of ROP treatment, further underscoring their unique characteristics.

Keywords: Myopia, Ocular Biometry, Refraction, Retinopathy of Prematurity

1. Cook A, White S, Batterbury M, Clark D. Ocular growth and refractive error development in premature infants with or without retinopathy of prematurity. Invest Ophthalmol Vis Sci 2008;49:5199–5207.

2. Abri Aghdam K, Khadamy J, Falavarjani KG, Tsui I. Refractive outcomes following the treatment of retinopathy of prematurity in the anti-VEGF era: A literature review. J AAPOS 2016;20:539–540.e533.

3. Wiecek E, Akula JD, Vanderveen DK, Mantagos IS, Wu C, Curran AL, et al. Longitudinal change of refractive error in retinopathy of prematurity treated with intravitreal bevacizumab or laser photocoagulation. Am J Ophthalmol 2022;240:252–259.

4. Hwang ES, Kassem IS, Allozi R, Kravets S, Al-Kirwi KY, Hallak JA, et al. Association between myopia progression and quantity of laser treatment for retinopathy of prematurity. PLoS One 2022;17:e0279898.

5. Chen YC, Chen SN. Foveal microvasculature, refractive errors, optical biometry and their correlations in schoolaged children with retinopathy of prematurity after intravitreal antivascular endothelial growth factors or laser photocoagulation. Br J Ophthalmol 2020;104:691–696.

6. Fieß A, Kölb-Keerl R, Knuf M, Kirchhof B, Blecha C, Oberacher-Velten I, et al. Axial length and anterior segment alterations in former preterm infants and full-term neonates analyzed with Scheimpflug Imaging. Cornea. 2017;36:821–827.

7. Geloneck MM, Chuang AZ, Clark WL, Hunt MG, Norman AA, Packwood EA, et al.; BEAT-ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol 2014;132:1327–1333.

8. Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: A 5-year retrospective analysis. Ophthalmology 2015;122:1008–1015.

9. Prakalapakorn SG, Sarin N, Sarin N, McGeehan B, Tran-Viet D, Tai V, et al. Evaluating the association of clinical factors and optical coherence tomography retinal imaging with axial length and axial length growth among preterm infants. Graefes Arch Clin Exp Ophthalmol 2021;259:2661–2669.

10. Simmons M, Wang J, Leffler JN, Li S, Morale SE, de la Cruz A, et al. Longitudinal development of refractive error in children treated with intravitreal bevacizumab or laser for retinopathy of prematurity. Transl Vis Sci Technol 2021;10:14.

11. Lu X, Zeng X, Chen M, Fan Z, Zheng L, Tian Y, et al. Refractive and biometrical characteristics of children with retinopathy of prematurity who received laser photocoagulation or intravitreal ranibizumab injection. Graefes Arch Clin Exp Ophthalmol 2022;260:3213–3219.

12. Prematurity* CoRo. The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 2005;123:991–999.

13. Davitt BV, Dobson V, Good WV, Hardy RJ, Quinn GE, Siatkowski RM, et al.; Early Treatment for Retinopathy of Prematurity Cooperative Group. Prevalence of myopia at 9 months in infants with high-risk prethreshold retinopathy of prematurity. Ophthalmology 2005;112:1564–1568.

14. Lenis TL, Gunzenhauser RC, Fung SS, Dhindsa YK, Sarraf D, Pineles SL, et al. Myopia and anterior segment optical coherence tomography findings in laser-treated retinopathy of prematurity eyes. J AAPOS 2020;24:86.e1–7.

15. Yang CS, Wang AG, Shih YF, Hsu WM. Long-term biometric optic components of diode laser-treated threshold retinopathy of prematurity at 9 years of age. Acta Ophthalmol 2013;91:e276–e282.

16. Gunay M, Sekeroglu MA, Bardak H, Celik G, Esenulku CM, Hekimoglu E, et al. Evaluation of refractive errors and ocular biometric outcomes after intravitreal bevacizumab for retinopathy of prematurity. Strabismus 2016;24:84–88. 8 JOURNAL